BridgeBio Pharma BBIO Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's retained earnings?
- BridgeBio Pharma (BBIO) reported retained earnings of -$3.99B in Q1 2026.
- How has BridgeBio Pharma's retained earnings changed year-over-year?
- BridgeBio Pharma's retained earnings decreased by 22.1% year-over-year, from -$3.26B to -$3.99B.
- What is the long-term trend for BridgeBio Pharma's retained earnings?
- Over 5 years (2020 to 2025), BridgeBio Pharma's retained earnings has grown at a 33.9% compound annual growth rate (CAGR), from -$888.76M to -$3.82B.
- What does retained earnings mean?
- Total profits kept in the business rather than paid out as dividends.
- How do you interpret retained earnings?
- A negative balance (accumulated deficit) is typical for early-stage biotech companies heavily investing in R&D, while a positive balance indicates long-term profitability.
- How does retained earnings compare across companies?
- Often negative for pre-commercial biotech firms; positive for established pharmaceutical companies.